Literature DB >> 7355437

Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin.

M Ali, J W McDonald, J J Thiessen, P E Coates.   

Abstract

Compressed and enteric-coated acetylsalicylate (ASA) tablets have been compared in normal healthy subjects. Plasma ASA and salicylate (SA) were measured by high pressure liquid chromatography (HPLC). Platelet cyclooxygenase activity in vitro was studied by a radiometric technique. Following ingestion of 650 mg of ASA in the form of compressed tablets, cyclooxygenase activity was inhibited 95% within 45 min. Enzyme activity was observed to increase within 8 h and reached 10% of control level by 24 h. The pattern suggests that only circulating platelets are affected by ASA ingestion. Following the administration of 650 mg of ASA as enteric-coated tablets comparable inhibition of cyclooxygenase activity was observed, although the effect was delayed, reflecting the delayed appearance of ASA in the plasma. Return to control levels followed a pattern similar to that observed with the compressed tablet.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7355437     DOI: 10.1161/01.str.11.1.9

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  14 in total

1.  Plasma drug and antiplatelet profiles of the original acetylsalicylic acid preparations used in the AMIS, PARIS and German-Austrian trials for secondary prevention of myocardial infarction.

Authors:  R Simrock; K Rehders; H Spahn; E Mutschler; H K Breddin
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt.

Authors:  L Aarons; K Hopkins; M Rowland; S Brossel; J F Thiercelin
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

3.  Biochemical selectivity of oral versus intravenous aspirin in rats. Inhibition by oral aspirin of cyclooxygenase activity in platelets and presystemic but not systemic vessels.

Authors:  C Cerletti; M C Gambino; S Garattini; G de Gaetano
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

4.  Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function.

Authors:  F Bochner; D B Williams; P M Morris; D M Siebert; J V Lloyd
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Aspirin for myocardial infarction. Clinical pharmacokinetic considerations.

Authors:  F Bochner; J V Lloyd
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

6.  [Reversible inhibition of thrombocyte stimulation by acetylsalicylic acid and its role in antithrombotic therapy].

Authors:  R Simrock; H Spahn; H K Breddin; E Mutschler
Journal:  Klin Wochenschr       Date:  1983-03-15

7.  Inhibition of platelet function by a controlled release acetylsalicylic acid formulation--single and chronic dosing studies.

Authors:  M S Roberts; L J McLeod; P A Cossum; J H Vial
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  The effects of varying doses of aspirin on human platelet activation induced by PAF, collagen and arachidonic acid.

Authors:  M L Taylor; N L Misso; G A Stewart; P J Thompson
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

9.  Plasma levels of aspirin following effervescent and enteric coated tablets, and their effect on platelet function.

Authors:  L M Ross-Lee; M J Elms; B E Cham; F Bochner; I H Bunce; M J Eadie
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Monitoring plasma concentrations of salicylate.

Authors:  M Mandelli; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.